• STAT+: Solicitor general recommends Supreme Court shouldn't review an Amgen patent case

    6 days ago - By STAT

    In a setback to Amgen, the U.S. solicitor general recommended that the Supreme Court not hear a case in which the company argued a federal appeals court incorrectly determined its patent claims on a cholesterol medication are invalid.
    The recommendation increases the likelihood that a long-running battle between Amgen and a pair of rivals - Sanofi and Regeneron Pharmaceuticals - over the market for injectable cholesterol treatments may finally be nearing an end. Amgen filed a lawsuit against the other companies in 2014 for allegedly infringing patents when they sought regulatory approval...
    Read more ...